Navigation Links
Pharmatech Oncology Launches New Data Management Business Unit
Date:4/24/2009

DENVER, April 24 /PRNewswire/ -- Pharmatech Oncology, Inc., a Research Management Organization (RMO) headquartered in Denver, Colorado, announces the launch of their Data Management business unit to the bioscience and pharmaceutical industries. The Pharmatech Oncology Data Management business unit is branded as C(3)DM (Customized, Consistent, and Clinical Data Management). The Data Management business unit maintains and processes data for a broad range of clinical trials in various therapeutic areas, not only in the fields of oncology and hematology.

In managing clinical data projects, the C(3)DM business unit has built a solid data system platform focused around the EDC (electronic data capture) solution TrialMaster(TM) from OmniComm Systems, Inc.(TM) The platform is designed to be customized to incorporate all of the clinical data aspects involved in each individual clinical trial. "The Data Management team has worked extremely hard over the last few months to develop a fully-integrated solution for data capture and patient accrual for a lymphoma trial. Our unique platform gives clients access to a wide-range of capabilities by having their data managed through a trusted and reliable source, while also having our clinical sites trained by the creators of the system," states Jason Lones, Clinical Data Manager.

The data management business unit focuses on customized data capture solutions for any clinical development marketplace. Data integrity throughout the data management process is assured by following FDA regulations, adhering to industry standard GCPs, and maintaining 21CFR Part 11 compliance.

About Pharmatech Oncology:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. The Data Management business entity manages data for all types of clinical research, along with in-house trials focused in oncology and hematology. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech Oncology, please visit www.pharmatechoncology.com.

About OmniComm:

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Chicago, Germany, Tula, Russia, California, New York, North Carolina, Tennessee, Massachusetts and Georgia.

Key Words: Cancer, Clinical Trials, Contract Research, Data Management, Network, Oncology, Patients, Research, Site Management


'/>"/>
SOURCE Pharmatech Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Schedules Fourth Quarter 2008 Earnings Release on Thursday, March 26, 2009
2. WuXi PharmaTech Announces CFO Benson Tsang to Leave Company; COO Edward Hu Named Acting CFO
3. WuXi PharmaTech Honored on the Deloitte Technology Fast 500 Asia Pacific 2008 List for the Fifth Consecutive Year
4. WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
5. WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference
6. WuXi PharmaTech Expands Collaboration for Fully Integrated Services
7. WuXi PharmaTech Announces Second Quarter 2008 Results
8. WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
9. Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
10. WuXi PharmaTech 2007 Annual Report Available Online
11. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, FACS , ... Top Doctor. The annual list identifies the nation’s top physicians, in a variety of ... it to the top of Castle Connolly’s coveted ranking. , Castle Connolly is the ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... A global ... has successfully opened clubfoot clinics in all 29 Indian states—bringing the country one step ... in Kangra, Himachal Pradesh, the nonprofit organization is on track to enroll 10,000 children ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... the endoscope after every reprocessing cycle, both between patient procedures and before storage, ... infections. Drying is as important to the prevention of disease transmission and nosocomial ...
(Date:8/16/2017)... ... August 16, 2017 , ... Fusion Flix Inc., a ... programming over four countries and millions of viewers in a partnership with the Amazon ... buy On-Demand and fully available on Blu Ray disc in 2018. Proceeds will be ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... eBook, 9781498499620    ) shares that during the time of a cancer diagnosis, surgery and ... God's love, and all the many ways God shows love to those who ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty ... 2017.  All comparisons, unless otherwise noted, are to the quarter ... Second Quarter 2017 Highlights include: ... of 3.5% Total prescriptions dispensed of 220,000, ... versus 7.6% Gross profit per prescription ...
(Date:8/2/2017)... Aug. 2, 2017 Fenita J. ... as a Pinnacle Lifetime Professional in the Field ... Manager at Turing Pharmaceuticals, AG. Her skills and ... relationship building.                ... 25 years of experience as a highly successful ...
Breaking Medicine Technology: